JP2004131403A - Skin care preparation for external use - Google Patents
Skin care preparation for external use Download PDFInfo
- Publication number
- JP2004131403A JP2004131403A JP2002295742A JP2002295742A JP2004131403A JP 2004131403 A JP2004131403 A JP 2004131403A JP 2002295742 A JP2002295742 A JP 2002295742A JP 2002295742 A JP2002295742 A JP 2002295742A JP 2004131403 A JP2004131403 A JP 2004131403A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- ursolic acid
- external preparation
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 229940096998 ursolic acid Drugs 0.000 claims abstract description 43
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims abstract description 43
- -1 ursolic acid glycoside Chemical class 0.000 claims abstract description 33
- 229930182470 glycoside Natural products 0.000 claims abstract description 19
- 150000002482 oligosaccharides Polymers 0.000 claims abstract description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims abstract description 8
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 150000002772 monosaccharides Chemical group 0.000 claims abstract description 8
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 claims description 3
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- OKPQBUWBBBNTOV-UHFFFAOYSA-N Kojibiose Natural products COC1OC(O)C(OC2OC(OC)C(O)C(O)C2O)C(O)C1O OKPQBUWBBBNTOV-UHFFFAOYSA-N 0.000 claims description 3
- VSRVRBXGIRFARR-CIYSLCTESA-N Neohesperidose Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 VSRVRBXGIRFARR-CIYSLCTESA-N 0.000 claims description 3
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- BUEBVQCTEJTADB-UHFFFAOYSA-N Sambubiose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)CO1 BUEBVQCTEJTADB-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 3
- VSRVRBXGIRFARR-OUEGHFHCSA-N alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O VSRVRBXGIRFARR-OUEGHFHCSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- PZDOWFGHCNHPQD-OQPGPFOOSA-N kojibiose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-OQPGPFOOSA-N 0.000 claims description 3
- QIGJYVCQYDKYDW-LCOYTZNXSA-N laminarabiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-LCOYTZNXSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims description 3
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 claims description 3
- BUEBVQCTEJTADB-IGQSMMPPSA-N sambubiose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1 BUEBVQCTEJTADB-IGQSMMPPSA-N 0.000 claims description 3
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 230000037303 wrinkles Effects 0.000 abstract description 4
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 47
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 23
- 238000000034 method Methods 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000008269 hand cream Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002194 synthesizing effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000036620 skin dryness Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QBLFZIBJXUQVRF-UHFFFAOYSA-N (4-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Br)C=C1 QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QURCVMIEKCOAJU-HWKANZROSA-N Isoferulic acid Natural products COC1=CC=C(\C=C\C(O)=O)C=C1O QURCVMIEKCOAJU-HWKANZROSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000008209 arabinosides Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000008311 hydrophilic ointment Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 150000003675 ursolic acids Chemical class 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- AQZLKGKBZLRIIU-UHFFFAOYSA-N 6-chloro-1,5-dimethylcyclohexa-2,4-dien-1-ol Chemical compound CC1=CC=CC(C)(O)C1Cl AQZLKGKBZLRIIU-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 0 CC(CCC1(*)CCC2(C)C3(C)CCC(C4(C)C)[C@]5(C)CCC4O*)C(C)C1C2=CCC35NC Chemical compound CC(CCC1(*)CCC2(C)C3(C)CCC(C4(C)C)[C@]5(C)CCC4O*)C(C)C1C2=CCC35NC 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 description 1
- 229920000061 Geraniin Polymers 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000003625 amylolytic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- FBJQEBRMDXPWNX-CFCQXFMMSA-N beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](O)O2)O)O1 FBJQEBRMDXPWNX-CFCQXFMMSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- NJEMMCIKSMMBDM-UHFFFAOYSA-N bis(2-ethoxyethyl) hexanedioate Chemical compound CCOCCOC(=O)CCCCC(=O)OCCOCC NJEMMCIKSMMBDM-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000001547 cellobiose group Chemical group 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- AFDXODALSZRGIH-UHFFFAOYSA-N p-coumaric acid methyl ether Natural products COC1=CC=C(C=CC(O)=O)C=C1 AFDXODALSZRGIH-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- AZJYLVAUMGUUBL-UHFFFAOYSA-A u1qj22mc8e Chemical compound [F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[F-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O=[Si]=O.O=[Si]=O.O=[Si]=O.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 AZJYLVAUMGUUBL-UHFFFAOYSA-A 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、皮膚外用剤に関し、詳しくは皮膚の乾燥に起因する状態を改善し、皮膚の水分保持機能を亢進し、皮膚に潤いを与える美肌効果を有する皮膚外用剤に関する。
【0002】
【従来の技術】
一般的に皮膚の乾燥は、皮膚分泌物の量、特に皮脂分泌量の減退により、角層のバリア機能が低下し、経表皮性水分損失(以下、TEWLと略す)が大きくなったときにおこる。
【0003】
例えば、冬季や、過剰な皮膚洗浄、年齢、体質などによる皮膚分泌物の減少により皮膚乾燥が増悪し、角層水分量が10%程度以下に低下した状態を特にドライスキンと称している。
【0004】
そして、皮膚を乾燥状態のままにしていると、皮膚のつやは低下し、小じわが目だつようになり、化粧のりが悪くなるなどの弊害がでてくる。
【0005】
これらの皮膚状態を改善するためには、角層水分含有量の低下を防止し、正常な皮膚機能を維持することが必要であり、健常な皮膚を保持する為に、従来は、皮膚に適度な水分と油分を与える親水性の皮膚保湿剤と油性の皮膚柔軟剤を皮膚外用剤に配合することが行われていた。
【0006】
例えば、上記皮膚保湿剤としては、アルギン酸、トレハロースなどの多糖類や少糖類、ソルビトール、エチレングリコール、グリセリン、プロピレングリコール、ポリチレングリコールなどの多価アルコール類、およびピロリドンカルボン酸ソーダ、乳酸ソーダなどの有機酸塩類等が利用されている。しかし、これらは皮膚の最外層である角質層の水分を吸水して、かえって皮膚の水分を損失する原因となることがあり、また、これらを多量に含有する皮膚外用剤は、べたつくなどの違和感を与えるなど問題があった。
【0007】
また、上記皮膚柔軟剤としては、流動パラフィン、ワセリン、オリーブ油、スクアラン、ラノリン、合成エステル油等が利用されている。しかし、これらを表皮からの水分蒸散を充分に防ぐ程度に皮膚外用剤に含有しようとすると、皮膚の正常なる新陣代謝を阻害する原因となることがあり問題があった。
【0008】
一方、ウルソール酸、ウルソール酸塩及びウルソール酸エステル類には、チロシナーゼ阻害活性に基づく美白効果、光老化防止効果、プロテアーゼ活性阻害効果などが知られており、これらを各種クリーム、ローション、ミルクなどの皮膚外用剤に配合することが知られている(例えば、特許文献1参照。)。
【0009】
しかし、ウルソール酸配糖体を含有する皮膚外用剤及びそのウルソール酸配糖体が示す効果については知られていない。
【0010】
【特許文献1】
特公平2−2848号
【0011】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、従来の皮膚外用剤の如く皮膚湿潤剤、皮膚柔軟剤を多量に配合する必要がなく、皮膚の正常な生理機能が妨げられる虞れもなく、肌あれ、つや不足、小じわ等の乾燥に起因する皮膚状態を改善し、充分な皮膚水分保持機能亢進により潤いを与えることができる、いわゆる美肌効果を有し、感触的にも問題のない皮膚外用剤を提供することを課題とする。
【0012】
【課題を解決するための手段】
本発明者は、上記課題を解決するため鋭意研究を行なった結果、ウルサン系のトリテルペノイドの一つであるウルソール酸の配糖体に、皮膚水分保持機能の亢進作用が高く、優れた美肌効果があることを見い出し、発明を完成させるに至った。
【0013】
すなわち、本発明は、以下のとおりである。
(1)下記一般式(I)で表されるウルソール酸配糖体を含有することを特徴とする皮膚外用剤。
【0014】
【化2】
(式中、Rは単糖類残基又はオリゴ糖類残基を表す。)
(2)前記一般式(I)のRで表される単糖類残基又はオリゴ糖類残基が、アラビノース、キシロース、リボース、リキソース、グルコース、ガラクトース、マンノース、タロース、フルクトース、マルトース、イソマルトース、セロビオース、ゲンチオビオース、コージビオース、ラミナリビオース、ニゲロース、サンブビオース、ネオヘスペリドース、マルトトリオース、イソマルトトリオース、ラフィノース、セロトリオース及びゲンチトリオースから選択される1種である(1)に記載の皮膚外用剤。
(3)ウルソール酸配糖体の含有量が皮膚外用剤全体に対して総量で0.001〜10重量%である(1)又は(2)の何れかに記載の皮膚外用剤。
【0015】
【発明の実施の形態】
以下、本発明を詳細に説明する。
【0016】
本発明の皮膚外用剤は、ウルソール酸配糖体を含有することを特徴とする。
【0017】
本発明に適用されるウルソール酸配糖体は、上記一般式(I)で示される化合物である。
【0018】
ここで上記一般式(I)のR基としては、単糖類残基又はオリゴ糖残基が挙げられる。
【0019】
オリゴ糖残基としては、二糖類〜六糖類のオリゴ糖残基が好ましく、中でも二糖類〜三糖類のオリゴ糖類残基が好ましい。
【0020】
また、単糖類残基及びオリゴ糖残基としては、例えばアラビノース、キシロース、リボース、リキソース、グルコース、ガラクトース、マンノース、タロース、フルクトース等の単糖類残基、マルトース、イソマルトース、セロビオース、ゲンチオビオース、コージビオース、ラミナリビオース、ニゲロース、サンブビオース、ネオヘスペリドース等の二糖類残基、マルトトリオース、イソマルトトリオース、ラフィノース、セロトリオース、ゲンチオトリオース等の三糖類残基などが挙げられる。中でもより好ましくはアラビノース残基、グルコース残基、ガラクトース残基、マルトース残基、セロビオース残基、ラフィノース残基などが挙げられる。
【0021】
ウルソール酸配糖体の具体例としては、ウルソール酸アラビノシド、ウルソール酸グルコシド、ウルソール酸ガラクトシド、ウルソール酸マンノシド、ウルソール酸マルトシド、ウルソール酸セロビオシド、ウルソール酸ラフィノシドなどが、好適なものとして挙げられる。
【0022】
また、ウルソール酸配糖体はその塩の形で配合されてもよい。塩の形で用いる場合の対塩基の種類としては、ナトリウム、カリウムなどのアルカリ金属、カルシウム、マグネシウムなどのアルカリ土類金属、モノエタノールアミン、ジエタノールアミン、トリエタノールアミンなどのアミン類、及びアンモニウム等が例示できる。
【0023】
次に、本発明に係るウルソール酸配糖体は、ウルソール酸を常法に従い酵素法などの生化学的方法又は有機化学的方法により配糖体化することにより合成することができる。以下、ウルソール酸マルトシドを例にとってその合成方法の一例を説明する。
【0024】
ウルソール酸とオクタ−O−アセチル−β−D−マルトピラノシルブロミドをジクロロメタン中で、テトラメチル尿素とシルバートリフレートとの混合触媒下、氷冷しながら窒素気流中で2時間反応させる。その後、ジクロロメタン層を蒸発乾固させ、シリカゲルカラムクロマトグラフィーで反応物を分画単離した後、ナトリウムメチラートを用いて脱アセチル化することにより、ウルソール酸マルトシドを得る。
【0025】
その他の配糖体化合物も、相当するピラノシルブロミド誘導体を用いて上記方法に準じて製造することができる。
【0026】
上記の如くして得られるウルソール酸配糖体は、糖残基の種類により性状は若干異なるものの、概ね吸湿性、無臭の粉末であり、水には微溶もしくは難溶であるが、多価アルコール類には可溶で、各種皮膚外用剤基剤に対して容易に配合しうるという長所を有する。
【0027】
本発明では、ウルソール酸配糖体の配合量は、通常、皮膚外用剤全体に対して総量で0.001〜10重量%、好ましくは、0.01〜1重量%である。0.001重量%より多ければ、水分保持機能亢進による美肌効果が十分期待できるからである。但し、10重量%を越えた量を用いても効果の増強は見られず、また溶解性も不十分となるため経済面からも10重量%より少なくてよいと考えられる。
【0028】
配合する方法としてはウルソール酸配糖体を多価アルコールを含む水相成分中に溶解した後、油層成分と混合する方法が好ましい。
【0029】
本発明の皮膚外用剤には、前述のウルソール酸配糖体の他に、医薬品、化粧品などに一般に用いられる各種成分、即ち水性成分、油性成分、粉末成分、界面活性剤、保湿剤、増粘剤、色剤、香料、抗酸化剤、pH調整剤、キレート剤、防腐剤、あるいは紫外線防御剤、抗炎症剤、創傷治癒剤、新陳代謝促進剤、美白剤等の薬剤を1種又は2種以上を配合することができる。
【0030】
水性成分としては、例えば水、低級アルコール(エタノール、プロパノール、イソプロパノール)等が挙げられる。
【0031】
油性成分としては、例えば高級脂肪酸類(ステアリン酸、パルミチン酸、ミリスチン酸、ラウリン酸、およびそれらのエステル等)、高級アルコール類(セタノール、ラノリンアルコール、ステアリルアルコール、セトステアリルアルコール等)及びワックス類(固形パラフィン、マイクロクリスタリンワックス、セレシンワックス、ポリエチレンワックス、蜜ロウ、木ロウ、カルナウバロウ、キャンデリラロウ等)、天然又は合成油状物質(スクワラン、流動パラフィン、ラノリン又はその誘導体、オリーブ油、椿油、綿実油、オレイルアルコール、ひまし油、ワセリン、アジピン酸ジエトキシエチルエステル、シリコンオイル、弗素オイル等)が挙げられる。
【0032】
粉末成分としては、例えばアルミニウム粉末、酸化チタン粉末、酸化亜鉛粉末、酸化鉄粉末、アクリル粉体、シリカビーズ、タルク、セリサイト等が挙げられる。
【0033】
界面活性剤としては、例えばレシチン、ポリオキシエチレンモノオレエート、ポリオキシエチレンセチルエーテル、ステアリン酸アルミニウム、オクチルドデカノール、新油型モノステアリン酸グリセリン、モノステアリン酸プロピレングリコール等が挙げられる。
【0034】
保湿剤としては、例えばグリセリン、プロピレングリコール、1,3−ブチレングリコール、ジプロピレングリコール、エチレングリコール、1,4−ブチレングリコール、ジグリセリン、トリグリセリン、ソルビット又はその誘導体、ポリエチレングリコール等の多価アルコール;グルコース、マルトース、マルチトール、ショ糖、フルクトース、スレイトール、エリスリトール、ソルビット、澱粉分解糖、ヒアルロン酸、コンドロイチン硫酸、加水分解コラーゲン、加水分解エラスチン、カルボキシメチルキチン、カゼインソーダ、ムチン、スフィンゴ糖脂質等が挙げられ、全体に対して0.1〜30重量%の範囲で配合される。
【0035】
増粘剤としては、例えばカルボキシビニルポリマー、CPゼリー、カルボキシメチルセルロース、カラギーナン、アルギン酸ナトリウム、ベントナイト、ビーガム、合成ヘクトライト等が挙げられる。
【0036】
抗酸化剤としては、例えばジブチル化ヒドロキシトルエン(BHT)、ブチル化ヒドロキシアニソール(BHA)、トコフェロ−ルピロ亜硫酸ナトリウム、ソジウムビサルフェート、酢酸トコフェロール等が挙げられる。
【0037】
pH調整剤としては、例えばクエン酸、乳酸、酒石酸、燐酸等が挙げられる。
【0038】
キレート剤としては、例えばEDTA(エチレンジアミンテトラ酢酸)、チオグリコ−ル酸、チオ乳酸、チオグリセリン等が挙げられる。
【0039】
防腐剤としては、例えばp−オキシ安息香酸のメチル、エチル、プロピル、ブチルエステル、フェノキシエタノール、o−フェニルフェノール、デヒドロ酢酸又はその塩、p−クレゾール、m−クレゾール、o−クロル−m−キシレノール等が挙げられる。
【0040】
紫外線防御剤としては、例えばアスコルビン酸又はその誘導体、イソフェルラ酸又はその塩、オキシベンゾン又はその誘導体、p−アミノ安息香酸又はその誘導体、ウロカニン酸又はその誘導体、コウジ酸、ジベンゾイルメタン又はその誘導体、p−メトキシ桂皮酸又はその誘導体、微粒子酸化チタン、微粒子酸化亜鉛、微粒子酸化鉄等が挙げられ、全体に対して0.01〜30重量%の範囲で配合される。
【0041】
抗炎症剤としては、例えばグリチルレチン酸又はその誘導体、グリチルリチン酸又はその誘導体、ビサボロール、ゲラニイン、マロニエ抽出物、アロエ抽出物等が挙げられ、全体に対して0.01〜5重量%の範囲で配合される。
【0042】
創傷治癒剤としては、ローヤルゼリー抽出物、当帰エキス、アラントイン又はその誘導体、ローズマリー抽出物、ロズマリン酸等が挙げられ、全体に対して0.01〜5重量%の範囲で配合される。
【0043】
新陳代謝促進剤としては、胎盤抽出物、γ−オリザノール、アミノ酸又はその誘導体、ビタミンE又はその誘導体等が挙げられ、全体に対して0.01〜5重量%の範囲で配合される。
【0044】
美白剤としては、パンテテイン−S−スルフォン酸、イソフェルラ酸、アスコルビン酸又はその燐酸マグネシウム塩、アルブチン、コウジ酸、リノール酸、トラネキサム酸、エスクリン、ビタミンA酸、レチノール等が挙げられる。
【0045】
これらの各成分又は薬剤はそれぞれ単独で又は2種以上混合して使用することができる。
【0046】
本発明の皮膚外用剤の剤型には特に制限はなく、通常医薬品、医薬部外品、化粧品などに用いられているもの、例えば軟膏、クリ−ム、乳液、ロ−ション、パック、浴用剤などの剤型が挙げられる。
【0047】
【実施例】
以下に、実施例を挙げて本発明について更に具体的に説明する。尚、以下で記載の配合割合は、重量%で表示するものとする。
【0048】
[実施例1] 柔軟化粧水
下記表1に示す柔軟化粧水を得た。尚、表1で用いたウルソール酸グルコシドは、上述したウルソール酸マルトシドの合成方法と同様な方法に従い製造したものである。
【0049】
【表1】
[実施例2] 乳液
下記表2に示す乳液を得た。尚、表2で用いたウルソール酸マルトシドは、上述した合成方法に従い製造したものである。
【0050】
【表2】
[実施例3] ハンドクリーム
下記表3に示すハンドクリームを得た。尚、表3で用いたウルソール酸ラフィノシドは、上述したウルソール酸マルトシドの合成方法と同様な方法に従い製造したものである。
【0051】
【表3】
[実施例4] 親水性軟膏
下記表4に示す親水性軟膏を得た。尚、表4で用いたウルソール酸セロビオシドは、上述したウルソール酸マルトシドの合成方法と同様な方法に従い製造したものである。
【0052】
【表4】
[実施例5] ゲル状化粧オイル
下記表5に示すゲル状化粧オイルを得た。尚、表5で用いたウルソール酸アラビノシドは、上述したウルソール酸マルトシドの合成方法と同様な方法に従い製造したものである。
【0053】
【表5】
[実施例6] ノンアルコール型化粧水
下記表6に示すノンアルコール型化粧水を得た。尚、表6で用いたウルソール酸ガラクトシドは、上述したウルソール酸マルトシドの合成方法と同様な方法に従い製造したものである。
【0054】
【表6】
[実施例7] 皮膚外用剤の評価
上記実施例2及び3に示した乳液、ハンドクリームを用いて、実使用テストを行ってその効力を確認した。
【0055】
比較品として、上記実施例2、3におけるウルソール酸配糖体を、公知の保湿剤であるトレハロースに置き換えて調製した乳液及びハンドクリーム(比較品1)、またウルソール酸に置き換えて調製した乳液及びハンドクリーム(比較品2)を用いた。
【0056】
試験方法を以下の通りである。
(試験方法)
乾燥肌を有する本邦成人女子150名を、それぞれ25人ずつ無作為に6群(A〜F群)に分けた。A群の顔面には、本発明品の乳液(実施例2の乳液)を、B群には比較品1の乳液を、C群には比較品2の乳液を、また、D群の手指には本発明品のハンドクリーム(実施例3のハンドクリーム)を、E群には比較品1のハンドクリームを、F群には比較品2のハンドクリームを、それぞれ6週間適用した。
【0057】
6週間後の種々評価要素の改善状態、及び自然増悪の状態について群間比較を行った。
【0058】
顔面乾燥肌の改善及び自然増悪の分布結果を表7に、手指乾燥肌の改善及び自然増悪の分布結果を表8にそれぞれ示す。尚、表7及び表8の評価において、+++は著明改善、++はかなり改善、+はやや改善、−は変化なしを表すものとする。
【0059】
【表7】
【0060】
【表8】
上記表7及び表8の結果から明らかなように、本発明品の乳液は比較品の乳液に比し、評価項目全般にわたって良好な結果が得られ、特に、乾燥感の改善が顕著であり、水分保持機能の亢進により美肌効果に優れていることが実証された。
【0061】
また、本発明品のハンドクリームについても、比較品のハンドクリームに比し、顕著な改善がみられ、水分保持機能の亢進により肌荒れなどの自然増悪抑制効果を有することが明らかとなった。
【0062】
尚、上記評価要素以外の意見として、本発明の皮膚外用剤は使用時におけるベタツキ感などの感触的な弊害は殆んどないことも同時に明らかとなった。
【0063】
【発明の効果】
本発明によれば、従来から知られている保湿剤などに比べて、皮膚が本来備えている水分保持機能を亢進することによって、肌あれ、つや不足、小じわ等の皮膚状態の改善、潤いの付与などの美肌効果が格段に優れている皮膚外用剤であって、使用時における感触においても弊害のない皮膚外用剤を提供することができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an external preparation for skin, and more particularly, to an external preparation for skin having an effect of improving skin dryness, enhancing the function of retaining moisture in the skin, and moisturizing the skin.
[0002]
[Prior art]
In general, skin dryness occurs when the amount of skin secretion, particularly the amount of sebum secretion, decreases, and the barrier function of the stratum corneum decreases, and transepidermal water loss (hereinafter abbreviated as TEWL) increases. .
[0003]
For example, a state in which skin dryness worsens due to a decrease in skin secretion due to winter or excessive skin washing, age, constitution, and the like, and a water content of the stratum corneum decreases to about 10% or less is particularly referred to as dry skin.
[0004]
If the skin is left in a dry state, the luster of the skin is reduced, fine wrinkles are noticeable, and adverse effects such as deterioration of the makeup glue appear.
[0005]
In order to improve these skin conditions, it is necessary to prevent a decrease in the water content of the stratum corneum and to maintain normal skin function. It has been practiced to incorporate a hydrophilic skin moisturizer and an oily emollient which give a good moisture and oil content into a skin external preparation.
[0006]
For example, as the skin moisturizer, alginic acid, polysaccharides and oligosaccharides such as trehalose, sorbitol, ethylene glycol, glycerin, propylene glycol, polyhydric alcohols such as polyethylene glycol, and sodium pyrrolidone carboxylate, sodium lactate and the like Organic acid salts and the like are used. However, they may absorb the water of the stratum corneum, the outermost layer of the skin, and cause the skin to lose water.In addition, skin external preparations containing a large amount of these may cause uncomfortable feelings such as stickiness. There was a problem such as giving.
[0007]
As the emollient, liquid paraffin, vaseline, olive oil, squalane, lanolin, synthetic ester oil and the like are used. However, if these are to be contained in the external preparation for skin to such an extent as to sufficiently prevent the evaporation of water from the epidermis, it may cause a problem in that normal skin metabolism of the skin is inhibited.
[0008]
On the other hand, ursolic acid, ursolic acid salts and ursolic acid esters are known to have a whitening effect based on tyrosinase inhibitory activity, a photoaging prevention effect, a protease activity inhibitory effect, etc., and these are used in various creams, lotions, milks and the like. It is known to be incorporated into a skin external preparation (for example, see Patent Document 1).
[0009]
However, skin external preparations containing ursolic acid glycoside and the effects of the ursolic acid glycoside are not known.
[0010]
[Patent Document 1]
Japanese Patent Publication No. 2-2848 [0011]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and it is not necessary to mix a large amount of a skin moisturizing agent and a skin softening agent as in a conventional external preparation for the skin, and the normal physiological function of the skin may be hindered. It has a so-called beautiful skin effect that can improve the skin condition caused by dryness such as rough skin, lack of luster, fine wrinkles, etc., and can provide sufficient moisture by enhancing skin moisture retention function. It is an object of the present invention to provide an external preparation for skin.
[0012]
[Means for Solving the Problems]
The present inventor has conducted intensive studies to solve the above-mentioned problems.As a result, ursolic acid glycoside, which is one of ursan triterpenoids, has a high skin moisture retention function, and has an excellent skin effect. He found something and completed the invention.
[0013]
That is, the present invention is as follows.
(1) An external preparation for skin, comprising a ursolic acid glycoside represented by the following general formula (I).
[0014]
Embedded image
(In the formula, R represents a monosaccharide residue or an oligosaccharide residue.)
(2) The monosaccharide residue or oligosaccharide residue represented by R in the general formula (I) is arabinose, xylose, ribose, lyxose, glucose, galactose, mannose, talose, fructose, maltose, isomaltose, cellobiose. (1) the external preparation for skin according to (1), which is one selected from gentioose, gentiobiose, kojibiose, laminaribiose, nigerose, sambubiose, neohesperidose, maltotriose, isomalttriose, raffinose, cellotriose, and gentitriose. .
(3) The skin external preparation according to any of (1) or (2), wherein the content of the ursolic acid glycoside is 0.001 to 10% by weight in total with respect to the whole skin external preparation.
[0015]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
[0016]
The external preparation for skin of the present invention is characterized by containing a ursolic acid glycoside.
[0017]
The ursolic acid glycoside applied to the present invention is a compound represented by the above general formula (I).
[0018]
Here, examples of the R group in the general formula (I) include a monosaccharide residue or an oligosaccharide residue.
[0019]
As the oligosaccharide residues, oligosaccharide residues of disaccharide to hexasaccharide are preferable, and oligosaccharide residues of disaccharide to trisaccharide are particularly preferable.
[0020]
Examples of the monosaccharide residues and oligosaccharide residues include, for example, arabinose, xylose, ribose, lyxose, glucose, galactose, mannose, talose, fructose, and other monosaccharide residues, maltose, isomaltose, cellobiose, gentiobiose, kojibiose, Examples include disaccharide residues such as laminaribiose, nigerose, sambubiose, and neohesperidose, and trisaccharide residues such as maltotriose, isomalttriose, raffinose, cellotriose, and gentiotriose. Among them, more preferred are an arabinose residue, a glucose residue, a galactose residue, a maltose residue, a cellobiose residue and a raffinose residue.
[0021]
Specific examples of the ursolic acid glycoside include arabinoside ursolic acid, glucoside ursolic acid, galactoside ursolic acid, mannoside ursolic acid, maltoside ursolic acid, cellobioside ursolic acid, raffinoside ursolic acid, and the like.
[0022]
The ursolic acid glycoside may be incorporated in the form of a salt thereof. When used in the form of a salt, examples of the type of counter base include alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, amines such as monoethanolamine, diethanolamine and triethanolamine, and ammonium. Can be illustrated.
[0023]
Next, the ursolic acid glycoside according to the present invention can be synthesized by glycosylation of ursolic acid by a biochemical method such as an enzymatic method or an organic chemical method according to a conventional method. Hereinafter, an example of the synthesis method of maltoside ursolic acid will be described.
[0024]
Ursolic acid and octa-O-acetyl-β-D-maltopyranosyl bromide are reacted in dichloromethane under a mixed catalyst of tetramethyl urea and silver triflate for 2 hours in a nitrogen stream while cooling with ice. Thereafter, the dichloromethane layer is evaporated to dryness, the reaction product is fractionated and isolated by silica gel column chromatography, and then deacetylated with sodium methylate to obtain maltoside ursolic acid.
[0025]
Other glycoside compounds can be produced according to the above method using the corresponding pyranosyl bromide derivative.
[0026]
The ursolic acid glycoside obtained as described above is generally a hygroscopic, odorless powder and slightly soluble or slightly soluble in water, though slightly different in properties depending on the type of sugar residue. It has the advantage that it is soluble in alcohols and can be easily blended with various skin external preparation bases.
[0027]
In the present invention, the amount of the ursolic acid glycoside is usually 0.001 to 10% by weight, preferably 0.01 to 1% by weight, based on the total amount of the external preparation for skin. If the content is more than 0.001% by weight, a beautiful skin effect due to the enhancement of the water retention function can be sufficiently expected. However, even if the amount exceeds 10% by weight, the effect is not enhanced, and the solubility becomes insufficient, so that it is considered that the amount may be less than 10% by weight from the economical viewpoint.
[0028]
As a method of blending, a method is preferred in which ursolic acid glycoside is dissolved in an aqueous phase component containing a polyhydric alcohol and then mixed with an oil phase component.
[0029]
In the skin external preparation of the present invention, in addition to the ursolic acid glycoside described above, various components generally used in pharmaceuticals, cosmetics, and the like, that is, aqueous components, oil components, powder components, surfactants, humectants, thickeners One or more agents such as agents, coloring agents, fragrances, antioxidants, pH adjusters, chelating agents, preservatives, or ultraviolet protective agents, anti-inflammatory agents, wound healing agents, metabolic accelerators, whitening agents, etc. Can be blended.
[0030]
Examples of the aqueous component include water, lower alcohols (ethanol, propanol, isopropanol) and the like.
[0031]
Examples of the oily component include higher fatty acids (stearic acid, palmitic acid, myristic acid, lauric acid, and esters thereof), higher alcohols (cetanol, lanolin alcohol, stearyl alcohol, cetostearyl alcohol, etc.) and waxes ( Solid paraffin, microcrystalline wax, ceresin wax, polyethylene wax, beeswax, wood wax, carnauba wax, candelilla wax, etc., natural or synthetic oils (squalane, liquid paraffin, lanolin or derivatives thereof, olive oil, camellia oil, cottonseed oil, oleyl) Alcohol, castor oil, petrolatum, diethoxyethyl adipate, silicone oil, fluorine oil, etc.).
[0032]
Examples of the powder component include aluminum powder, titanium oxide powder, zinc oxide powder, iron oxide powder, acrylic powder, silica beads, talc, and sericite.
[0033]
Examples of the surfactant include lecithin, polyoxyethylene monooleate, polyoxyethylene cetyl ether, aluminum stearate, octyl dodecanol, glycerin monostearate, propylene glycol monostearate, and the like.
[0034]
Examples of the humectant include polyhydric alcohols such as glycerin, propylene glycol, 1,3-butylene glycol, dipropylene glycol, ethylene glycol, 1,4-butylene glycol, diglycerin, triglycerin, sorbitol or derivatives thereof, and polyethylene glycol. Glucose, maltose, maltitol, sucrose, fructose, threitol, erythritol, sorbitol, amylolytic sugar, hyaluronic acid, chondroitin sulfate, hydrolyzed collagen, hydrolyzed elastin, carboxymethyl chitin, casein soda, mucin, glycosphingolipid, etc. And it is blended in the range of 0.1 to 30% by weight based on the whole.
[0035]
Examples of the thickener include carboxyvinyl polymer, CP jelly, carboxymethylcellulose, carrageenan, sodium alginate, bentonite, veegum, synthetic hectorite, and the like.
[0036]
Examples of the antioxidant include dibutylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), sodium tocopherol-pyrosulfite, sodium bisulfate, and tocopherol acetate.
[0037]
Examples of the pH adjuster include citric acid, lactic acid, tartaric acid, phosphoric acid and the like.
[0038]
Examples of the chelating agent include EDTA (ethylenediaminetetraacetic acid), thioglycolic acid, thiolactic acid, thioglycerin and the like.
[0039]
As the preservative, for example, methyl, ethyl, propyl, butyl ester of p-oxybenzoic acid, phenoxyethanol, o-phenylphenol, dehydroacetic acid or a salt thereof, p-cresol, m-cresol, o-chloro-m-xylenol and the like Is mentioned.
[0040]
Examples of the ultraviolet ray protective agent include ascorbic acid or its derivative, isoferulic acid or its salt, oxybenzone or its derivative, p-aminobenzoic acid or its derivative, urocanic acid or its derivative, kojic acid, dibenzoylmethane or its derivative, p -Methoxycinnamic acid or a derivative thereof, fine-particle titanium oxide, fine-particle zinc oxide, fine-particle iron oxide, and the like, and are added in an amount of 0.01 to 30% by weight based on the whole.
[0041]
Examples of the anti-inflammatory agent include glycyrrhetinic acid or a derivative thereof, glycyrrhizic acid or a derivative thereof, bisabolol, geraniin, malonier extract, aloe extract, and the like, and are contained in an amount of 0.01 to 5% by weight based on the whole. Is done.
[0042]
Examples of the wound healing agent include royal jelly extract, Toki extract, allantoin or its derivative, rosemary extract, rosmarinic acid, and the like, and are blended in an amount of 0.01 to 5% by weight based on the whole.
[0043]
Examples of the metabolic promoter include placenta extract, γ-oryzanol, amino acid or its derivative, vitamin E or its derivative, and the like, and are added in an amount of 0.01 to 5% by weight based on the whole.
[0044]
Examples of whitening agents include pantethein-S-sulfonic acid, isoferulic acid, ascorbic acid or a magnesium phosphate thereof, arbutin, kojic acid, linoleic acid, tranexamic acid, esculin, vitamin A acid, retinol and the like.
[0045]
Each of these components or drugs can be used alone or in combination of two or more.
[0046]
There is no particular limitation on the form of the external preparation for skin of the present invention, and those usually used for pharmaceuticals, quasi-drugs, cosmetics, etc., for example, ointments, creams, emulsions, lotions, packs, bath preparations And other dosage forms.
[0047]
【Example】
Hereinafter, the present invention will be described more specifically with reference to examples. In addition, the compounding ratio described below shall be shown by weight%.
[0048]
[Example 1] Soft lotion A soft lotion shown in Table 1 below was obtained. The ursolic acid glucoside used in Table 1 was produced according to a method similar to the method for synthesizing ursolic acid maltoside described above.
[0049]
[Table 1]
Example 2 Emulsion Emulsion shown in Table 2 below was obtained. The ursolic acid maltoside used in Table 2 was produced according to the above-described synthesis method.
[0050]
[Table 2]
Example 3 Hand Cream A hand cream shown in Table 3 below was obtained. The raffinoside ursolic acid used in Table 3 was produced according to a method similar to the method for synthesizing maltoside ursolic acid described above.
[0051]
[Table 3]
[Example 4] Hydrophilic ointment A hydrophilic ointment shown in Table 4 below was obtained. The ursolic acid cellobioside used in Table 4 was produced according to a method similar to the above-mentioned method for synthesizing ursolic acid maltoside.
[0052]
[Table 4]
[Example 5] Gel cosmetic oil A gel cosmetic oil shown in Table 5 below was obtained. The arabinoside ursolic acid used in Table 5 was produced according to a method similar to the method for synthesizing maltoside ursolic acid described above.
[0053]
[Table 5]
Example 6 Non-alcohol type lotion A non-alcohol type lotion shown in Table 6 below was obtained. The ursolic acid galactoside used in Table 6 was produced according to a method similar to the above-described method for synthesizing ursolic acid maltoside.
[0054]
[Table 6]
[Example 7] Evaluation of external preparation for skin Using the emulsion and hand cream shown in Examples 2 and 3 above, an actual use test was performed to confirm the efficacy.
[0055]
As comparative products, emulsions and hand creams prepared by replacing the ursolic acid glycosides in Examples 2 and 3 with trehalose, which is a known humectant, and emulsions prepared by replacing ursolic acid with ursolic acid, Hand cream (comparative product 2) was used.
[0056]
The test method is as follows.
(Test method)
150 Japanese adult women with dry skin were randomly divided into 6 groups (A to F groups) by 25 persons each. The emulsion of the product of the present invention (the emulsion of Example 2) was applied to the face of Group A, the emulsion of Comparative Product 1 was applied to Group B, the emulsion of Comparative Product 2 was applied to Group C, and the fingers of Group D were applied to the fingers. Was applied with the hand cream of the present invention (the hand cream of Example 3), the hand cream of the comparative product 1 was applied to the group E, and the hand cream of the comparative product 2 was applied to the group F for 6 weeks.
[0057]
Comparison between groups was performed on the state of improvement of various evaluation factors and the state of spontaneous deterioration after 6 weeks.
[0058]
Table 7 shows the distribution results of improvement and spontaneous exacerbation of dry face skin, and Table 8 shows the distribution results of improvement and spontaneous exacerbation of dry hand skin. In the evaluations of Tables 7 and 8, +++ represents a marked improvement, ++ represents a considerable improvement, + represents a slight improvement, and − represents no change.
[0059]
[Table 7]
[0060]
[Table 8]
As is evident from the results of Tables 7 and 8, the emulsion of the product of the present invention has better results over all evaluation items than the emulsion of the comparative product, and in particular, the improvement in dry feeling is remarkable. It was proved that the enhancement of the water retention function was excellent in the beautiful skin effect.
[0061]
The hand cream of the present invention also showed a remarkable improvement as compared with the hand cream of the comparative product, and it was clarified that it had an effect of suppressing natural exacerbation such as rough skin due to enhanced water retention function.
[0062]
In addition, as an opinion other than the above evaluation factors, it was also clarified that the external preparation for skin of the present invention had almost no harmful effects such as stickiness during use.
[0063]
【The invention's effect】
According to the present invention, compared to conventionally known moisturizing agents and the like, by enhancing the moisture retention function originally provided by the skin, rough skin, lack of luster, improvement of skin conditions such as fine wrinkles, moisturizing. It is a skin external preparation that is extremely excellent in skin beautiful effects such as imparting, and has no adverse effect on the feel during use.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002295742A JP3763810B2 (en) | 2002-10-09 | 2002-10-09 | Topical skin preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002295742A JP3763810B2 (en) | 2002-10-09 | 2002-10-09 | Topical skin preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004131403A true JP2004131403A (en) | 2004-04-30 |
JP2004131403A5 JP2004131403A5 (en) | 2005-06-02 |
JP3763810B2 JP3763810B2 (en) | 2006-04-05 |
Family
ID=32285902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002295742A Expired - Fee Related JP3763810B2 (en) | 2002-10-09 | 2002-10-09 | Topical skin preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3763810B2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006036713A (en) * | 2004-07-29 | 2006-02-09 | Maruzen Pharmaceut Co Ltd | Antioxidant agent, anti-inflammatory agent, beautifying agent, and skin cosmetic |
WO2006132033A1 (en) * | 2005-06-10 | 2006-12-14 | Pola Chemical Industries Inc. | Novel triterpenic acid derivative and preparation for external application for skin comprising the same |
JP2007008902A (en) * | 2005-07-04 | 2007-01-18 | Maruzen Pharmaceut Co Ltd | Anti-inflammatory agent, antioxidation agent, skin whitening agent, skin cosmetic product, food and drink |
JP2007161611A (en) * | 2005-12-12 | 2007-06-28 | Pola Chem Ind Inc | Skin care preparation for improving skin barrier function |
JP2007332066A (en) * | 2006-06-14 | 2007-12-27 | Nikko Chemical Co Ltd | Tyrosinase production inhibitor |
EP2050454A1 (en) * | 2006-08-10 | 2009-04-22 | House Wellness Foods Corporation | Moisturizing agent |
JP2012001520A (en) * | 2010-06-21 | 2012-01-05 | Pola Chemical Industries Inc | Composition |
-
2002
- 2002-10-09 JP JP2002295742A patent/JP3763810B2/en not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006036713A (en) * | 2004-07-29 | 2006-02-09 | Maruzen Pharmaceut Co Ltd | Antioxidant agent, anti-inflammatory agent, beautifying agent, and skin cosmetic |
US7718635B2 (en) | 2005-06-10 | 2010-05-18 | Pola Chemical Industries Inc. | Triterpenic acid derivative and preparation for external application for skin comprising the same |
WO2006132033A1 (en) * | 2005-06-10 | 2006-12-14 | Pola Chemical Industries Inc. | Novel triterpenic acid derivative and preparation for external application for skin comprising the same |
JP5080249B2 (en) * | 2005-06-10 | 2012-11-21 | ポーラ化成工業株式会社 | Novel triterpenic acid derivative and external preparation for skin containing the same |
CN101193907B (en) * | 2005-06-10 | 2012-07-11 | 宝丽化学工业有限公司 | Novel triterpenic acid derivative and external application agent for skin comprising the same |
JP2007008902A (en) * | 2005-07-04 | 2007-01-18 | Maruzen Pharmaceut Co Ltd | Anti-inflammatory agent, antioxidation agent, skin whitening agent, skin cosmetic product, food and drink |
JP4722595B2 (en) * | 2005-07-04 | 2011-07-13 | 丸善製薬株式会社 | Anti-inflammatory agents, antioxidants and whitening agents, and skin cosmetics |
JP2007161611A (en) * | 2005-12-12 | 2007-06-28 | Pola Chem Ind Inc | Skin care preparation for improving skin barrier function |
JP4528745B2 (en) * | 2006-06-14 | 2010-08-18 | 日光ケミカルズ株式会社 | Tyrosinase production inhibitor |
JP2007332066A (en) * | 2006-06-14 | 2007-12-27 | Nikko Chemical Co Ltd | Tyrosinase production inhibitor |
EP2050454A4 (en) * | 2006-08-10 | 2009-09-23 | House Wellness Foods Corp | Moisturizing agent |
EP2050454A1 (en) * | 2006-08-10 | 2009-04-22 | House Wellness Foods Corporation | Moisturizing agent |
US8231882B2 (en) | 2006-08-10 | 2012-07-31 | House Wellness Foods Corporation | Moisturizer |
JP2012001520A (en) * | 2010-06-21 | 2012-01-05 | Pola Chemical Industries Inc | Composition |
Also Published As
Publication number | Publication date |
---|---|
JP3763810B2 (en) | 2006-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100929264B1 (en) | External skin preparation | |
EP1600143B1 (en) | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE | |
JP5080249B2 (en) | Novel triterpenic acid derivative and external preparation for skin containing the same | |
KR20010014687A (en) | Oily material composition | |
WO2009116450A1 (en) | Elastase activity inhibitor | |
JP3302525B2 (en) | External preparation for skin | |
JPH11246339A (en) | Preparation for external use for skin | |
JP3763810B2 (en) | Topical skin preparation | |
US20080050331A1 (en) | Cosmetic Composition Containing A Protease Activator | |
JP4080946B2 (en) | Skin preparation | |
JP2004115381A (en) | External preparation for skin | |
JPH1192326A (en) | Skin preparation for external use | |
JP2010037251A (en) | Skin external preparation | |
CN112135599B (en) | Skin whitening agent | |
JP2004131388A (en) | Skin care preparation for external use | |
JPH10147514A (en) | Cosmetic | |
JP4076477B2 (en) | Skin preparation | |
JP2001199873A (en) | Composition for external use | |
EP1916993B1 (en) | Cosmetic composition containing a protease activator | |
JP2002234828A (en) | Skin whitening cosmetic preparation | |
JP2860902B2 (en) | External preparation for skin | |
JP2000053529A (en) | Agent for external use for skin | |
JP6051047B2 (en) | Skin external preparation for hair | |
JP3340930B2 (en) | Melanin production inhibitor and whitening cosmetic | |
JP2000063255A (en) | Preparation for external use for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Effective date: 20040819 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
A621 | Written request for application examination |
Effective date: 20040819 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Effective date: 20060110 Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060117 |
|
R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |